About Nura Bio
Nura Bio is a company based in San Francisco (United States) founded in 2018 by Marc Freeman and Steve McKnight. Nura Bio has raised $214.8 million across 3 funding rounds from investors including The Column Group, Samsara BioCapital and Sanofi Ventures. Nura Bio offers products and services including Neuroprotective Therapies. Nura Bio operates in a competitive market with competitors including Enliven Therapeutics, Nuvalent, Abbisko Therapeutics, NewAmsterdam Pharma and Healx, among others.
- Headquarter San Francisco, United States
- Founders Marc Freeman, Steve McKnight
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nura Bio ™ Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$214.8 M (USD)
in 3 rounds
-
Latest Funding Round
$73.8 M (USD), Series B
Jun 22, 2026
-
Investors
The Column Group
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nura Bio
Nura Bio offers a comprehensive portfolio of products and services, including Neuroprotective Therapies.
Targets pathways for axon degeneration in neurological diseases.
People of Nura Bio
Unlock access to complete
Funding Insights of Nura Bio
Nura Bio has successfully raised a total of $214.8M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $73.8 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nura Bio
Nura Bio has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include The Column Group, Samsara BioCapital and Sanofi Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Locked | Locked | Locked |
Investor details for Nura Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nura Bio
Investment portfolio details for Nura Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nura Bio
Detailed financials for Nura Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nura Bio Comparisons
Peer comparison for Nura Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nura Bio
Nura Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enliven Therapeutics, Nuvalent, Abbisko Therapeutics, NewAmsterdam Pharma and Healx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for solid tumours and blood cancers
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| Locked | Locked | Locked |
Developing novel small molecule drugs for immunomodulatory pathways to treat cancer
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for rare diseases is developed.
|
Detailed competitors of Nura Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nura Bio
Complete news archive for Nura Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nura Bio
Nura Bio was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Nura Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Alpna Seth is the current CEO of Nura Bio.
Nura Bio is a funded company, having raised a total of $214.8M across 3 funding rounds to date.
NUraBio provides a solution for the diagnosis of a neurological disorder and neuroprotective medicines. The company targets the axonal degeneration and neuroimmune regulation for treating neurological disorders. It also argeting neuron-intrinsic mechanisms and the neuron-glia axis. The lead candidate of the company is small molecule-based SARM1 which is an axon-intrinsic metabolic sensor and regulator with putative immune function. The company also offers tools like x-ray crystallography, cryo-EM, and biophysical platforms for drug discovery, along with genetic screening and biomarker platforms for the identification of translatable biomarkers.
Nura Bio's top competitors include Nuvalent, Enliven Therapeutics and Healx.
Nura Bio offers Neuroprotective Therapies.
Nura Bio has 4 investors. Key investors include The Column Group, Samsara BioCapital, Sanofi Ventures, and Euclidean Capital.